Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — December 2020

Planlagt Fastgjort Låst Flyttet Genmab
1.1k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • Legolas23L Offline
    Legolas23L Offline
    Legolas23
    wrote on sidst redigeret af
    #415

    Kan du give et kort sum-op @Sukkeralf. Det kræver medlemskab at læse artiklen.

    1 Reply Last reply
    0
    • E Offline
      E Offline
      E_L
      wrote on sidst redigeret af
      #416

      "I think broadly now, that we’ve seen whenever we add daratumumab to the standard of care, whatever that may be, we seem to see a significant improvement in progression-free survival and improving depth of response,” he said. https://www.hcplive.com/view/daratumumab-pomalidomide-relapsed-refractory-multiple-myeloma

      1 Reply Last reply
      0
      • S Offline
        S Offline
        Sukkeralf
        wrote on sidst redigeret af
        #417

        Legolas ikke så meget nyt - artiklen mener nok at JNJ/Legends CAR-T er i førertrøjen omend de døjer med lidt neurotox. Regenron og JNJs BaAbs kommer vel ind som nummer to. Amgens BsAbs lider begge. BCMA ADC har for lav responsrate og AEs, hvor specielt ocular tox er et problem. Så ingen direkte vinder endnu....

        1 Reply Last reply
        0
        • SolsenS Offline
          SolsenS Offline
          Solsen
          wrote on sidst redigeret af
          #418

          Jeg har læst et sted, at Regenerons BCMA er bedre på safety end JNJs, men har ikke haft tid til at studere det nærmere.

          1 Reply Last reply
          0
          • Legolas23L Offline
            Legolas23L Offline
            Legolas23
            wrote on sidst redigeret af
            #419

            Takker 🙂

            1 Reply Last reply
            0
            • E Offline
              E Offline
              E_L
              wrote on sidst redigeret af
              #420

              has anyone been able to see the Tahamtan Ahmadi talk & Q&A?

              1 Reply Last reply
              0
              • G Offline
                G Offline
                GeorgeBest
                wrote on sidst redigeret af
                #421

                No, I think it is only for people registered for ASH

                1 Reply Last reply
                0
                • E Offline
                  E Offline
                  E_L
                  wrote on sidst redigeret af
                  #422

                  yes, but i was hoping someone here had some contacts and saw it regardless...

                  1 Reply Last reply
                  0
                  • S Offline
                    S Offline
                    Sukkeralf
                    wrote on sidst redigeret af
                    #423

                    E L I guess we will have more or less the same talk tonight

                    1 Reply Last reply
                    0
                    • E Offline
                      E Offline
                      E_L
                      wrote on sidst redigeret af
                      #424

                      probably, only, i imagine on the talk yesterday the questions would be from doctors, this evening from analysts -that might give a different perspective , if you know what i mean.

                      1 Reply Last reply
                      0
                      • E Offline
                        E Offline
                        E_L
                        wrote on sidst redigeret af
                        #425

                        talking about analysts, i was a bit surprised that Sydbank had not yet included anything on epco "Han har endnu ikke har indregnet de nye midler som eksempelvis epicoritamab i sine egne modeller, men siger at de også kommer med i beregningerne i takt med at flere data bliver offentliggjort" https://www.euroinvestor.dk/nyheder/sydbank-saerdeles-positive-data-fra-genmabs-nye-studie

                        1 Reply Last reply
                        0
                        • E Offline
                          E Offline
                          E_L
                          wrote on sidst redigeret af
                          #426

                          Ola Landgren, M.D.
                          @DrOlaLandgren

                          Daratumumab + KRd & Daratumumab + VRd = 2 most effective combos for newly diagnosed #myeloma in 2020/2021

                          1 Reply Last reply
                          0
                          • E Offline
                            E Offline
                            E_L
                            wrote on sidst redigeret af
                            #427

                            Camidanlumab https://twitter.com/YucaiWangMD/status/1336127652860751873

                            1 Reply Last reply
                            0
                            • BulderB Offline
                              BulderB Offline
                              Bulder
                              wrote on sidst redigeret af
                              #428

                              Hutching: Glofi og epco https://haematologisktidsskrift.dk/sygdomme/lymfoma/786-bispecifikke-antistoffer-viser-stadig-imponerende-responsrater-mod-lymfekraeft.html

                              1 Reply Last reply
                              0
                              • BulderB Offline
                                BulderB Offline
                                Bulder
                                wrote on sidst redigeret af
                                #429

                                Plesner: Maia https://haematologisktidsskrift.dk/sygdomme/myeloma/792-langtidsresultater-viser-forsat-pfs-fordele-ved-tillaeg-af-darazalex-til-rd.html

                                1 Reply Last reply
                                0
                                • BulderB Offline
                                  BulderB Offline
                                  Bulder
                                  wrote on sidst redigeret af
                                  #430

                                  Mere Glofi: https://haematologisktidsskrift.dk/sygdomme/lymfoma/793-kombi-af-to-bispecifikke-antistoffer-kan-blive-serios-konkurrent-til-car-t.html

                                  1 Reply Last reply
                                  0
                                  • SolsenS Offline
                                    SolsenS Offline
                                    Solsen
                                    wrote on sidst redigeret af
                                    #431

                                    Har Genmab en CD19 x 4-1BB eller bliver det en mangelvare i samarbejdet med med Abbvie ? Eller kan CD37 gøre en forskel.

                                    1 Reply Last reply
                                    0
                                    • BulderB Offline
                                      BulderB Offline
                                      Bulder
                                      wrote on sidst redigeret af
                                      #432

                                      Tror ikke vi kommer til at savne kombi-partnere til Epco. Vi har jo Abvie med på vognen, og en af Winkels pointer var netop, at Abvie er fremme i skoene på det hæmatologiske område.

                                      1 Reply Last reply
                                      0
                                      • G Offline
                                        G Offline
                                        GeorgeBest
                                        wrote on sidst redigeret af
                                        #433

                                        Tak Bulder. Denne paragraf er super: „Med så flotte data i relapseret/refraktær sygdom, så er det næste naturlige skridt at rykke de bispecifikke antistoffer frem i behandlingslinjerne – ultimativt helt frem i første linje. Det helt store formål er jo at øge det kurative potentiale så meget som muligt. Det er dét, der tæller for patienterne og for virksomhederne.”

                                        1 Reply Last reply
                                        0
                                        • G Offline
                                          G Offline
                                          GeorgeBest
                                          wrote on sidst redigeret af
                                          #434

                                          Så er spørgsmålet, kan Epcoritamab ikke blive til mere en 4 bn $ i topsalg?

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger